CohBar (CWBR) 10-K 29 Mar 22 2021 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2021	Mar. 24, 2022	Jun. 30, 2021
Document Information Line Items
Entity Registrant Name	CohBar, Inc.
Trading Symbol	CWBR
Document Type	10-K
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		86,981,684
Entity Public Float			$ 69,343,744
Amendment Flag	false
Entity Central Index Key	0001522602
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Non-accelerated Filer
Entity Well-known Seasoned Issuer	No
Document Period End Date	Dec. 31, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	FY
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
ICFR Auditor Attestation Flag	false
Document Annual Report	true
Document Transition Report	false
Entity File Number	001-38326
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	26-1299952
Entity Address, Address Line One	1455 Adams Drive
Entity Address, Address Line Two	Suite 2050
Entity Address, City or Town	Menlo Park
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94025
City Area Code	(650)
Local Phone Number	446-7888
Title of 12(b) Security	Common Stock, par value $0.001 per share
Security Exchange Name	NASDAQ
Entity Interactive Data Current	Yes
Auditor Firm ID	688
Auditor Name	Marcum llp
Auditor Location	New York, NY

Balance Sheets

Balance Sheets - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 4,992,145	$ 2,894,575
Investments	21,253,866	18,120,266
Vendor receivable	173,499
Prepaid expenses and other current assets	527,380	413,692
Total current assets	26,946,890	21,428,533
Property and equipment, net	260,612	394,004
Intangible assets, net	19,309	18,075
Other assets	69,620	67,403
Total assets	27,296,431	21,908,015
Current liabilities:
Accounts payable	371,993	727,599
Accrued liabilities	196,020	1,141,741
Accrued payroll and other compensation	754,314	853,335
Note payable, net of debt discount and offering costs of $8,723 and $15,656 as of December 31, 2021 and 2020, respectively	366,277	349,344
Total current liabilities	1,688,604	3,072,019
Notes payable, net of debt discount and offering costs of $0 and $26,159 as of December 31, 2021 and 2020, respectively		348,841
Total liabilities	1,688,604	3,420,860
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.001 par value, Authorized 5,000,000 shares; No shares issued and outstanding as of December 31, 2021 and December 31, 2020, respectively
Common stock, $0.001 par value, Authorized 180,000,000 shares; Issued and outstanding 86,339,567 shares as of December 31, 2021 and 61,117,524 as of December 31, 2020	86,340	61,118
Additional paid-in capital	110,255,549	87,684,323
Accumulated deficit	(84,734,062)	(69,258,286)
Total stockholders’ equity	25,607,827	18,487,155
Total liabilities and stockholders’ equity	$ 27,296,431	$ 21,908,015

Balance Sheets (Parentheticals)

Balance Sheets (Parentheticals) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Net of debt discount and offering costs (in Dollars)	$ 8,723	$ 15,656
Debt discount of note payable and offering costs, current (in Dollars)	$ 0	$ 26,159
Preferred stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Preferred stock, authorized	5,000,000	5,000,000
Preferred stock, issued
Preferred stock, outstanding
Common stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Common stock, authorized	180,000,000	180,000,000
Common stock, issued	86,339,567	61,117,524
Common stock, outstanding	86,339,567	61,117,524

Statement of Operations

Statement of Operations - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Statement [Abstract]
Revenues
Operating expenses:
Research and development	7,705,090	6,937,610
General and administrative	7,703,065	6,261,905
Total operating expenses	15,408,155	13,199,515
Operating loss	(15,408,155)	(13,199,515)
Other income (expense):
Interest income	5,578	41,149
Interest expense	(40,108)	(311,410)
Equity modification expense		(2,290,688)
Amortization of debt discount and offering costs	(33,091)	(504,497)
Total other expense	(67,621)	(3,065,446)
Net loss	$ (15,475,776)	$ (16,264,961)
Basic and diluted net loss per share (in Dollars per share)	$ (0.23)	$ (0.33)
Weighted average common shares outstanding - basic and diluted (in Shares)	66,629,458	48,814,353

Statements of Changes in Stockh

Statements of Changes in Stockholders’ Equity - USD ($)	Common Stock	Additional Paid-in-Captial	Accumulated Deficit	Total
Balance at Dec. 31, 2019	$ 43,069	$ 61,087,082	$ (52,993,325)	$ 8,136,826
Balance (in Shares) at Dec. 31, 2019	43,069,418
Stock-based compensation		2,216,316		2,216,316
Equity modification expense		2,290,688		2,290,688
Exercise of employee stock options	$ 224	252,161		252,385
Exercise of employee stock options (in Shares)	223,924
Exercise of warrants	$ 20	44,980		45,000
Exercise of warrants (in Shares)	20,000
Sale of common stock in ATM, net	$ 2,350	4,306,002		4,308,352
Sale of common stock in ATM, net (in Shares)	2,350,067
Sale of common stock in CMPO, net	$ 12,300	13,643,231		13,655,531
Sale of common stock in CMPO, net (in Shares)	12,300,000
Issuance of equity to convert debt	$ 3,155	3,843,863		3,847,018
Issuance of equity to convert debt (in Shares)	3,154,115
Net loss			(16,264,961)	(16,264,961)
Balance at Dec. 31, 2020	$ 61,118	87,684,323	(69,258,286)	18,487,155
Balance (in Shares) at Dec. 31, 2020	61,117,524
Stock-based compensation		2,543,712		2,543,712
Issuance of common stock for ESPP plan	$ 18	16,796		16,814
Issuance of common stock for ESPP plan (in Shares)	17,662
Exercise of employee stock options	$ 1,262	1,239,228		1,240,490
Exercise of employee stock options (in Shares)	1,262,146
Exercise of warrants	$ 1,450	2,088,026		2,089,476
Exercise of warrants (in Shares)	1,451,025
Sale of common stock in ATM, net	$ 1,658	2,883,128		2,884,786
Sale of common stock in ATM, net (in Shares)	1,657,876
Sale of common stock in CMPO, net	$ 20,834	13,800,336		13,821,170
Sale of common stock in CMPO, net (in Shares)	20,833,334
Net loss			(15,475,776)	(15,475,776)
Balance at Dec. 31, 2021	$ 86,340	$ 110,255,549	$ (84,734,062)	$ 25,607,827
Balance (in Shares) at Dec. 31, 2021	86,339,567

Statements of Cash Flows

Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Cash flows from operating activities:
Net loss	$ (15,475,776)	$ (16,264,961)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	140,914	156,664
Stock-based compensation	2,543,712	2,216,316
Equity modification expense		2,290,688
Amortization of debt discount	31,687	463,781
Amortization of debt issuance costs	1,405	40,716
Discount on investments	(1,600)	2,734
Changes in operating assets and liabilities:
Vendor receivable	(173,499)
Prepaid expenses and other current assets	(113,688)	(52,381)
Accounts payable	(355,606)	282,823
Accrued liabilities	(945,721)	909,567
Accrued payroll and other compensation	(99,021)	175,580
Net cash used in operating activities	(14,447,193)	(9,778,473)
Cash flows from investing activities:
Purchases of property and equipment	(6,397)	(25,912)
Payment for security deposit	(2,217)	(3,161)
Patent costs	(2,359)
Purchases of investments	(43,601,000)	(25,417,000)
Proceeds from redemptions of investments	40,469,000	7,294,000
Net cash used in investing activities	(3,142,973)	(18,152,073)
Cash flows from financing activities:
Proceeds from ESPP plan	16,814
Proceeds from public offering	15,000,000	15,024,450
Costs of public offering	(1,178,830)	(1,368,919)
Proceeds from the At-the-Market Offering	2,980,595	4,409,738
Costs of At-the-Market Offering	(95,809)	(101,386)
Proceeds from exercise of warrants	2,089,476	45,000
Repayment of promissory notes	(365,000)
Proceeds from exercise of employee stock options	1,240,490	252,385
Net cash provided by financing activities	19,687,736	18,261,268
Net increase (decrease) in cash and cash equivalents	2,097,570	(9,669,278)
Cash and cash equivalents at beginning of period	2,894,575	12,563,853
Cash and cash equivalents at end of period	4,992,145	2,894,575
Non-cash financing activities:
Conversion of Promissory Notes to Common Stock		3,847,018
Supplemental disclosure of cash flow information:
Cash paid for income taxes	1,332	1,300
Cash paid for interest	$ 89,908

Business Organization and Natur

Business Organization and Nature of Operations	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
BUSINESS ORGANIZATION AND NATURE OF OPERATIONS	Note 1 – Business Organization and Nature of Operations CohBar, Inc. (“CohBar,” “its” or the “Company”) is a clinical stage biotechnology company exploiting the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases. The Company’s primary activities include utilizing its MITO+ platform to identify and develop novel peptide analogs, the research and development of its pipeline, securing intellectual property protection for its discoveries and assets, managing collaborations and clinical trials with contract research organizations (“CROs”) and raising capital to fund the Company’s operations. To date, the Company has not generated any revenues from operations and does not expect to generate any revenues in the near future. The Company has financed its operations primarily with proceeds from sales of its equity securities, private placements, the exercise of outstanding warrants and stock options and the issuance of debt instruments. The Company is monitoring the COVID-19 pandemic, which continues to rapidly evolve, and has taken steps to mitigate the potential impacts on its business. The extent to which the pandemic may impact the Company’s business, preclinical studies and its clinical trial will depend on future developments, which are highly uncertain and cannot be predicted with confidence. The Company has modified its business practices by restricting nonessential travel, implementing a partial work from home policy for its employees and instituting new safety protocols for its lab to enable essential on-site work to continue. The Company expects to continue to take actions that are in the best interests of its employees and business partners. Due to the uncertainty surrounding the pandemic, the Company’s visibility into the duration of these actions is limited.

Liquidity and Management_s Plan

Liquidity and Management’s Plans	12 Months Ended
	Dec. 31, 2021
Liquidity and Management’s Plan [Abstract]
LIQUIDITY AND MANAGEMENT’S PLANS	Note 2 – Liquidity and Management’s Plans As of December 31, 2021, the Company had a cash, cash equivalents and investments balance of $26.2 million and working capital and stockholders’ equity of $25.3 million and $25.6 million, respectively. During the year ended December 31, 2021, the Company incurred a net loss of $15.5 million. As reflected in the financial statements, the Company had an accumulated deficit as of December 31, 2021 and 2020, as well as recurring losses and negative cash flows from operating activities from inception. These factors raise substantial doubt about the Company’s ability to continue as a going concern for at least one year from the issuance of these financial statements. However, based on current budget assumptions, projected cash burn and the Company’s latitude to manage that cash burn and the cash and investments on hand as of December 31, 2021, the Company believes that it has sufficient capital to meet its operating expenses and obligations for the next twelve months from the date of this filing. However, if unanticipated difficulties or circumstances arise, the Company may require additional capital sooner to support its operations. If the Company is unable to raise additional capital whenever necessary, it may be forced to decelerate or curtail its research and development activities and/or other operations until such time as additional capital becomes available. Such limitation of the Company’s activities would allow it to slow its rate of spending and extend its use of cash until additional capital is raised. There can be no assurance that such a plan would be successful. There is no assurance that additional financing will be available when needed or that the Company will be able to obtain such financing on reasonable terms.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	Note 3 – Summary of Significant Accounting Policies Basis of Presentation All amounts are presented in U.S. Dollars. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at dates of the financial statements and the reported amounts of revenue and expenses during the periods. Actual results could differ from these estimates. The Company’s significant estimates and assumptions include the fair value of financial instruments, stock-based compensation and the valuation allowance relating to the Company’s deferred tax assets. Concentrations of Credit Risk The Company maintains deposits in a financial institution which is insured by the Federal Deposit Insurance Corporation (“FDIC”). At various times, the Company has deposits in this financial institution in excess of the amount insured by the FDIC. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk. Investments Investments as of December 2021 and 2020 consist of U.S. Treasury Bills, which are classified as held-to-maturity, and Certificates of Deposit totaling $21.3 million and $18.1 million, respectively. The Company determines the appropriate balance sheet classification of its investments at the time of purchase and evaluates the classification at each balance sheet date. All of the Company’s U.S. Treasury Bills mature within the subsequent twelve months from the date of purchase. Unrealized gains and losses were de minimus Capitalization of Patent Costs The Company capitalizes the costs of its patents which consists of legal and filing fees related to the prosecution of patent filings. The patents will be amortized using the straight-line method over the estimated remaining lives of the patents which is 20 years from the initial filing of the patent. Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. As of December 31, 2021, the Company invested $0.7 million in Treasury Bills that are considered cash equivalents due to their maturity date being less than three months from the date of purchase. Property and Equipment, net Property and equipment are stated at cost less accumulated depreciation. Depreciation of computer and lab equipment is computed by use of the straight-line method based on the estimated useful lives of the assets, which range from three to five years. Expenditures for maintenance and repairs that do not improve or extend the expected lives of the assets are expensed to operations, while expenditures for major upgrades to existing items are capitalized. Upon retirement or other disposition of these assets, the costs and accumulated depreciation are removed from the accounts and resulting gains or losses are reflected in the results of operations. Fair Value of Financial Instruments The Company measures the fair value of financial assets and liabilities based on the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company utilizes three levels of inputs that may be used to measure fair value: Level 1 - quoted prices in active markets for identical assets or liabilities. Level 2 - quoted prices for similar assets and liabilities in active markets or inputs that are observable. Level 3 - inputs that are unobservable (for example, cash flow modeling inputs based on assumptions). The carrying amounts of cash, investments and accounts payable approximate fair value due to the short-term nature of these instruments. The amount of debt included in the accompanying balance sheets approximates its fair value because the interest rate of the notes approximates the current market interest rate. Common Stock Purchase Warrants The Company classifies as equity any contracts that (i) require physical settlement or net-share settlement or (ii) provides the Company with a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement) providing that such contracts are indexed to the Company’s own stock. The Company classifies as assets or liabilities any contracts that (i) require net-cash settlement (including a requirement to net cash settle the contract if an event occurs and if that event is outside the Company’s control), or (ii) gives the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement). The Company assesses classification of its common stock purchase warrants and other free-standing derivatives at each reporting date to determine whether a change in classification between assets, liabilities and equity is required. The Company’s free-standing derivatives consist of warrants to purchase common stock that were issued in connection with its notes payable and public and private offerings. The Company evaluated these warrants to assess their proper classification using the applicable criteria enumerated under U.S. GAAP and determined that the common stock purchase warrants meet the criteria for equity classification in the accompanying balance sheets as of December 31, 2021 and 2020. Income Taxes The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of items that have been included or excluded in the financial statements or tax returns. Deferred tax assets and liabilities are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (“temporary differences”) at enacted tax rates in effect for the years in which the temporary differences are expected to reverse. The benefit of tax positions taken or expected to be taken in income tax returns are recognized in the financial statements if such positions are more likely than not of being sustained. Management has evaluated and concluded that there were no material uncertain tax positions requiring recognition in the Company’s financial statements as of December 31, 2021 and 2020. The Company does not expect any significant changes in the unrecognized tax benefits within twelve months of the reporting date. The Company classifies interest expense and any related penalties related to income tax uncertainties as a component of income tax expense. No interest or penalties have been recognized during the years ended December 31, 2021 and 2020. Research and Development Expenses The Company expenses all research and development expenses as incurred. These costs include payroll, employee benefits, supplies, contracted for lab services, depreciation and other personnel-related costs associated with product development. Share-Based Payment The Company accounts for share-based payments using the fair value method. For employees and directors, the fair value of the award is measured, as discussed below, on the grant date. For non-employees, fair value is generally valued based on the fair value of the services provided or the fair value of the equity instruments on the measurement date, whichever is more readily determinable. The Company has granted stock options at exercise prices equal to the closing price of the Company’s common stock as reported by Nasdaq, with input from management on the date of grant. Upon exercise of an option or warrant, the Company issues new shares of common stock out of its authorized shares. The weighted-average fair value of options and warrants has been estimated on the grant date or measurement date using the Black-Scholes pricing model. The fair value of each instrument is estimated on the grant date or measurement date utilizing certain assumptions for a risk-free interest rate, volatility and expected remaining lives of the awards. The risk-free interest rate used is the United States Treasury rate for the day of the grant having a term equal to the life of the equity instrument. Volatility was derived from the Company’s share price. The assumptions used in calculating the fair value of share-based payment awards represent management’s best estimates, but these estimates involve inherent uncertainties and the application of management judgment. As a result, if factors change and the Company uses different assumptions, the Company’s stock-based compensation expense could be materially different in the future. The Black-Scholes assumptions are as follows: For the 2021 2020 Expected life 6 years 6 years Risk free interest rate 0.90-1.38% 0.21-1.61% Expected volatility 91-92% 94-97% Expected dividend yield 0% 0% As of December 31, 2021, total unrecognized stock compensation expense was $6.0 million, which will be recognized as those options vest over a period of approximately four years. The amount of future stock option compensation expense could be affected by any future option grants or by any option holders leaving the Company before their grants are fully vested. Net Loss Per Share of Common Stock Basic net loss per share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted net earnings per share reflects the potential dilution that could occur if securities or other instruments to issue common stock were exercised or converted into common stock. Potentially dilutive securities are excluded from the computation of diluted net loss per share as their inclusion would be anti-dilutive and consist of the following: As of 2021 2020 Options 10,992,335 7,469,891 Warrants 35,634,075 19,372,818 Totals 46,626,410 26,842,709 Recent Accounting Pronouncements In December 2019, the Financial Accounting Standards Board issued ASU No. 2019-12, “Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes” (“ASU 2019-12”), which is intended to simplify the accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. Upon adoption, ASU No. 2019-12 did not have an impact on the Company’s consolidated financial statements and related disclosures.

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
PROPERTY AND EQUIPMENT	Note 4 – Property and Equipment Property and equipment consist of the following: As of 2021 2020 Lab equipment $ 860,433 $ 860,433 Computer and equipment 72,062 65,665 Total property and equipment $ 932,495 $ 926,098 Less: accumulated depreciation (671,883 ) (532,094 ) Total property and equipment, net $ 260,612 $ 394,004 Depreciation expense related to property and equipment for the years ended December 31, 2021 and 2020 was $0.1 million and $0.2 million, respectively.

Intangible Assets

Intangible Assets	12 Months Ended
	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
INTANGIBLE ASSETS	Note 5 – Intangible Assets Intangible assets consist of the following: As of 2021 2020 Intangible assets: patents $ 23,963 $ 21,604 Less: amortization (4,654 ) (3,529 ) Total intangible assets, net $ 19,309 $ 18,075 Amortization expense for each of the years ended December 31, 2021 and 2020 was $1,125 and $1,079, respectively. The Company will recognize intangible amortization expense of $1,226 in each of the next five years. Thereafter, amortization expense will total $13,184.

Accrued Liabilities

Accrued Liabilities	12 Months Ended
	Dec. 31, 2021
Accrued Liabilities [Abstract]
ACCRUED LIABILITIES	Note 6 – Accrued Liabilities Accrued liabilities consist of the following: As of 2021 2020 Lab services & supplies $ 6,080 $ 917,194 Professional fees 73,090 44,171 Interest 112,932 162,731 Other 3,918 17,645 Total accrued liabilities $ 196,020 $ 1,141,741

Notes Payable

Notes Payable	12 Months Ended
	Dec. 31, 2021
Debt Disclosure [Abstract]
NOTES PAYABLE	Note 7 – Notes Payable During the year ended December 31, 2020, the Company completed a private offering (the “Private Offering”) with certain promissory note holders converting outstanding amounts due in 2021 and 2022 under its 8% Unsecured Promissory Notes (the “Notes”). The Company converted the Notes in the Private Offering totaling an aggregate of $3.8 million in principal and interest and issued 3.2 million units at a price of $1.22 per unit. Two officers of the Company participated in the private offering converting an aggregate of approximately $0.1 million into 0.1 million units. Each unit consists of one share of the Company’s common stock and one warrant to purchase 0.75 of one share of the Company’s common stock at an exercise price of $1.44 per share. Each warrant can be exercised on or prior to June 18, 2026. As of December 31, 2021 and 2020, the aggregate principal balance of the promissory notes totaling $0.4 million and $0.8 million, respectively, remained outstanding. Of such amounts, $0.4 million in aggregate principal amount is due and payable in June 2022 and $0.4 million was repaid in the year ended December 31, 2021.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	Note 8 – Commitments and Contingencies Litigations, Claims and Assessments The Company may from time to time be a party to litigation and subject to claims incident to the ordinary course of business. As the Company grows and gains prominence in the marketplace it may become a party to an increasing number of litigation matters and claims. The outcome of litigation and claims cannot be predicted with certainty, and the resolution of these matters could materially affect the Company’s future results of operations, cash flows or financial position. The Company is not currently a party to any legal proceedings. Licensing Agreements The Company is a party to an Exclusive License Agreement (the “2011 Exclusive Agreement”) with the Regents of the University of California (“the Regents” or “Licensors”) which remains in effect for the life of the last-to-expire patent or last to be abandoned patent application, whichever is later. The Company agreed to pay the Licensors specified development milestone payments aggregating up to $765,000 for the first product sold under the license. Milestone payments for additional products developed and sold under the license are reduced by 50%. The Company is also required to pay annual maintenance fees to the Licensors. Aggregate maintenance fees for the first five years following execution of the agreement were $80,000. Thereafter, the Company is required to pay maintenance fees of $50,000 annually until the first sale of a licensed product. In addition, for the duration of the 2011 Exclusive Agreement, the Company is required to pay the Licensors royalties equal to 2% of its worldwide net sales of drugs, therapies or other products developed from claims covered by the licensed patents, subject to a minimum royalty payment of $75,000 annually, beginning after the first commercial sale of a licensed product. The Company is required to pay royalties ranging from 8% of worldwide sublicense sales of covered products (if the sublicense is entered after commencement of Phase II clinical trials) to 12% of worldwide sublicense sales (if the sublicense is entered prior to commencement of Phase I clinical trials). The agreement also requires the Company to meet certain diligence and development milestones, including filing of an Investigational New Drug (“IND”) Application for a product covered by the agreement on or before the seventh anniversary of the agreement date. In October 2021, the Regents accepted the Company’s payment for an additional year of license maintenance. Through December 31, 2021, no royalties have been incurred under the agreement. All maintenance fees due and payable have been paid. The Company is also a party to an Exclusive License Agreement (the “2013 Exclusive Agreement”) with the Regents whereby the Regents granted to the Company an exclusive license for the use of certain other patents. The 2013 Exclusive Agreement remains in effect for the life of the last-to-expire patent or last to be abandoned patent application, whichever is later. The Company paid the Regents an initial license issue fee of $10,000 for these other patents, which was charged to General and Administrative expense, as incurred. The Company is also required to pay annual maintenance fees to the Licensors. Aggregate maintenance fees for the first three years following execution of the agreement were $7,500. Thereafter, the Company is required to pay maintenance fees of $5,000 annually until the first sale of a licensed product. The Company agreed to pay the Regents specified development milestone payments aggregating up to $765,000 for the first product sold under the 2013 Exclusive Agreement. Milestone payments for additional products developed and sold under the 2013 Exclusive Agreement are reduced by 50%. In addition, for the duration of the 2013 Exclusive Agreement, the Company is required to pay the Regents royalties equal to 2% of the Company’s worldwide net sales of drugs, therapies or other products developed from claims covered by the licensed patent, subject to a minimum royalty payment of $75,000 annually, beginning after the first commercial sale of a licensed product. The Company is required to pay the Regents royalties ranging from 8% of worldwide sublicense sales of covered products (if the sublicense is entered after commencement of Phase II clinical trials) to 12% of worldwide sublicense sales (if the sublicense is entered prior to commencement of Phase I clinical trials). The agreement also requires the Company to meet certain diligence and development milestones, including filing of an IND Application for a product covered by the agreement on or before the seventh anniversary of the agreement date. Through December 31, 2021, no royalties have been incurred under the agreement. All maintenance fees due and payable have been paid. Operating Leases The Company is a party to a lease agreement for laboratory space leased on a month-to-month basis that is part of a shared facility in Menlo Park, California. In September 2021, the Company renewed its lease for office space in Fairfield, New Jersey for an additional year at the same annual cost of $13,080 per annum. Rent expense amounted to $0.4 million in each of the years ended December 31, 2021 and 2020.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
INCOME TAXES	Note 9 – Income Taxes The tax effects of temporary differences that give rise to deferred tax assets are as follows: As of 2021 2020 Current: Accrued expenses $ 144,077 $ 464,042 Stock compensation 1,800,762 869,815 Net operating loss carryforward 19,481,137 16,165,927 Research and development credit carry forward 252,536 548,983 Total deferred tax assets 21,678,512 18,048,767 Valuation allowance (21,678,512 ) (18,048,767 ) Deferred tax asset, net of valuation allowance $ - $ - A reconciliation of the statutory federal income tax rate to the Company’s effective tax rate is as follows: For the 2021 2020 U.S. statutory federal rate (21.0 )% (21.0 )% State income taxes, net of federal tax (7.0 )% (7.0 )% Federal tax rate change - % - % Permanent differences 2.5 % 0.4 % Prior year true-ups 2.7 % (0.4 )% R&D tax credit (0.1 )% (0.5 )% Change in valuation allowance 22.9 % 28.5 % Income tax provision (benefit) - % - % The income tax provision consists of the following: For the 2021 2020 Federal Current $ - $ - Deferred (2,723,112 ) (3,482,375 ) State and local Current - - Deferred (905,577 ) (1,158,072 ) Change in valuation allowance 3,628,689 4,640,447 Income tax provision (benefit) $ - $ - The Company assesses the likelihood that deferred tax assets will be realized. To the extent that realization is not more-likely-than-not, a valuation allowance is established. Based upon the Company’s losses since inception, management believes that it is more-likely-than-not that future benefits of deferred tax assets will not be realized. Therefore, the Company established a full valuation allowance as of December 31, 2021 and 2020. As of December 31, 2021 and 2020, the change in valuation allowance was $3.6 million and $4.6 million, respectively. The Company files income tax returns in the U.S. federal jurisdiction and various state jurisdictions, principally California and New Jersey. The Company is subject to examination by the various taxing authorities. The Company’s federal and state income tax returns for tax years beginning in 2018 remain subject to examination. At December 31, 2021 and 2020, the Company had approximately $70.0 million and $58.0 million, respectively, of federal and state net operating loss (“NOLs”) carryovers that may be available to offset future taxable income. The Company’s 2017 and prior federal and state net operating loss carry forwards, if not utilized, will begin to expire from 2029 to 2037. Beginning with 2018, and for subsequent years, the Company’s NOLs will have indefinite lives for federal tax purposes. In addition, net operating losses arising from prior years are also subject to examination at the time they are utilized in future years. In accordance with Section 382 of the Internal Revenue Code, the usage of the Company’s net operating loss carryforward could be limited in the event of a change in ownership. At this time, the Company has not completed a full study to assess whether an ownership change under Section 382 of the Code occurred due to the costs and complexities associated with such a study. The Company’s gross R&D tax credits were approximately $0.9 million as of December 31, 2021 and 2020. These R&D tax credits will begin to expire from 2033 to 2040, respectively. Coronavirus Aid, Relief, and Economic Security Act On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act, (“CARES Act”), was enacted and signed into law. GAAP requires recognition of the tax effects of new legislation during the reporting period that includes the enactment date. The CARES Act, among other things, includes changes to the tax provisions that benefits business entities. It also makes certain technical corrections to the 2017 Tax Cuts and Jobs Act and permits offsetting 100% of taxable income for taxable years beginning before 2021 through NOLs, carryovers and carrybacks. In addition, the CARES Act allows NOLs incurred in 2018, 2019, and 2020 to be carried back to each of the five preceding taxable years to generate a refund of previously paid income taxes. The CARES Act also includes other stimulus measures and reliefs. The Company has evaluated the impact of the CARES Act and determined that it did not have an impact on its financial statements or internal controls over financial reporting.

Stockholders_ Equity

Stockholders’ Equity	12 Months Ended
	Dec. 31, 2021
Stockholders' Equity Note [Abstract]
STOCKHOLDERS’ EQUITY	Note 10 – Stockholders’ Equity Authorized Capital The Company has authorized the issuance and sale of up to 185 million shares of stock, consisting of 180 million shares of common stock having a par value of $0.001 and 5 million shares of Preferred Stock having a par value of $0.001 per share. As of December 31, 2021 and 2020, there were no shares of Preferred Stock outstanding and there were no declared but unpaid dividends or undeclared dividend arrearages on any shares of the Company’s capital stock. At-the-Market Offering During the year ended December 31, 2020, the Company entered into an At-the-Market Offering Sales Agreement (“ATM”) with Virtu Americas, LLC as sales agent. During the year ended December 31, 2021, the Company sold 1.7 million shares of its common stock under the ATM program for proceeds of $2.9 million, net of commissions. The Company incurred professional fees of $21,294 related to the ATM and recognized those costs as a reduction to additional paid-in capital in the accompanying condensed balance sheets. During the year ended December 31, 2020, the Company sold 2.4 million shares of its common stock under the ATM program for proceeds of $4.3 million, net of commissions and professional fees of $0.2 million. As of December 31, 2021, the Company had $12.5 million available in its ATM program. Underwritten Public Offerings During the year ended December 31, 2021, the Company completed an underwritten public offering of its securities (the “Public Offering”) pursuant to which it sold 20.8 million shares of its common stock and warrants to purchase up to 20.8 million shares of common stock for proceeds of $13.8 million, net of commissions and professional fees of approximately $1.2 million. The warrants issued in the Public Offering were immediately exercisable and have a term of five years and a per share exercise price of $0.72. During the year ended December 31, 2020, the Company completed an underwritten public offering of the Company’s securities (the “Public Offering”) pursuant to which the Company sold 12.3 million shares of its common stock and warrants to purchase 10.6 million shares of common stock for proceeds of $13.7 million, net of commissions and professional fees of $1.4 million. The warrants issued in the Public Offering were immediately exercisable and have a term of five years and a per share exercise price of $1.44. Stock Options The Company has an incentive stock plan, the Amended and Restated 2011 Equity Incentive Plan (the “2011 Plan”), and has granted stock options to employees, non-employee directors and consultants from the 2011 Plan. Options granted under the 2011 Plan may be Incentive Stock Options or Non-statutory Stock Options, as determined by the Administrator at the time of grant. During the year ended December 31, 2020, the Company’s stockholders approved an amendment to the 2011 Plan to increase the number of shares authorized for issuance under the 2011 Plan to a total of 14 million. As of December 31, 2021, there were 3.2 million shares remaining available for issuance under the 2011 Plan. During the year ended December 31, 2021, the Company granted stock options to employees to purchase 6.3 million shares of the Company’s common stock, including the time and performance-based Inducement Awards, with grant date prices that ranged between $0.34 to $1.38 per share. The stock options have terms of ten years and are subject to vesting based on continuous service of the awardee over periods ranging from three to four years. The stock options have an aggregate grant date fair value of $5.8 million. In connection with the appointment of Joseph Sarret as the Company’s Chief Executive Officer, the Company entered into an Inducement Stock Option Agreement with Dr. Sarret on May 3, 2021. Pursuant to such agreement, the Company granted Dr. Sarret (1) a time-based inducement nonqualified stock option to purchase 2.3 million shares of common stock and (2) a performance-based inducement nonqualified stock option to purchase 1.3 million shares of common stock (the “Inducement Awards”). The options have an exercise price of $1.35, and the time-based grant will vest as to 25% of the shares on the one-year anniversary of the grant date, May 3, 2021, with the remaining shares subject to the option vesting in 36 equal monthly installments. The time-based Inducement Award has an aggregate grant date fair value of $2.2 million. As of December 31, 2021, Dr. Sarret satisfied a portion of the performance conditions and vested performance-based stock options to purchase 0.7 million shares of the 1.3 million shares possible under the grant. The performance-based award had a fair value of $0.1 million. During the year ended December 31, 2021, stock options to purchase 1.3 million shares of common stock were exercised for cash proceeds of $1.2 million. During the year ended December 31, 2021, stock options to purchase 1.5 million shares of common stock were cancelled and returned to the option pool for future issuance. During the year ended December 31, 2020, the Company granted stock options to employees to purchase 0.3 million shares of the Company’s common stock at exercise prices that ranged between $1.55 to $2.56 per share. The options have terms of ten years. The stock options have an aggregate grant date fair value of $0.5 million. During the year ended December 31, 2020, stock options to purchase 0.2 million shares of common stock were exercised for cash proceeds of $0.3 million. During the year ended December 31, 2020, stock options to purchase 0.2 million shares of common stock were cancelled and returned to the option pool for future issuance. The Company recorded stock-based compensation as follows: For the 2021 2020 Research and development $ 223,476 $ 604,107 General and administrative 2,320,236 1,612,209 Total $ 2,543,712 $ 2,216,316 The following table represents stock option activity for the years ended December 31, 2021 and 2020: Weighted Average Aggregate Stock Options Exercise Price Fair Value Contractual Intrinsic Outstanding Exercisable Outstanding Exercisable Vested Life (Years) Value Balance – January 1, 2020 7,632,358 4,542,144 $ 2.21 $ 1.57 $ 1.57 6.44 $ - Granted 275,000 - - - - - - Exercised (223,924 ) - - - - - - Cancelled (213,543 ) - - - - - - Balance – December 31, 2020 7,469,891 5,390,431 $ 2.06 $ 1.68 $ 1.68 6.27 $ - Granted 6,314,000 - - - - - - Exercised (1,262,146 ) - - - - - - Cancelled (1,529,410 ) - - - - - - Balance – December 31, 2021 10,992,335 6,126,901 $ 1.71 $ 1.58 $ 1.58 6.27 $ 36,273 The following table summarizes information on stock options outstanding and exercisable as of December 31, 2021: Grant Price Weighted Average Exercise Total Number Weighted Average From To Price Outstanding Exercisable Remaining Contractual Term $ 0.26 $ 2.02 $ 1.21 7,981,377 2,965,298 7.98 years $ 2.10 $ 4.60 $ 2.47 2,567,958 2,718,604 6.73 years $ 5.30 $ 8.86 $ 6.44 443,000 443,000 6.35 years Totals 10,992,335 6,126,901 Warrants During the year ended December 31, 2021, the Company granted warrants to two service providers to purchase a total of 0.1 million shares of its common stock with an exercise price of $1.38 per share. Fifty thousand of these warrants were valued using the Black-Scholes option pricing model and the corresponding expense will be recognized over the service period of three years. Ten thousand of these warrants were performance based. During the year ended December 31, 2021, the performance criteria were met and the warrants were valued and expensed at the time the performance conditions were met. The warrants have terms that range from two to three years with vesting over a one-year period. During the year ended December 31, 2021, warrants to purchase 1.5 million shares of common stock were exercised for cash proceeds of $2.1 million. During the year ended December 31, 2021, warrants to purchase 3.2 million shares of common stock expired and were cancelled. During the year ended December 31, 2020, the Company issued warrants to purchase 10.6 million shares of the Company’s common stock as part of the Public Offering (see Note 10 – Underwritten Public Offerings) and to the note holders that extended the due date of their unsecured promissory notes (see Note 10 – Amendments to Notes and Warrants) and warrants to purchase 2.4 million shares of the Company’s common stock as part of the Private Offering that converted outstanding amounts due under the Company’s 8% Unsecured Promissory Notes due 2021 (see Note 7 - Notes Payable). During the year ended December 31, 2020, warrants to purchase 20,000 shares of common stock were exercised for cash proceeds of $45,000. The following table represents warrant activity for the years ended December 31, 2021 and 2020: Weighted Average Aggregate Warrants Exercise Price Fair Value Contractual Intrinsic Outstanding Exercisable Outstanding Exercisable Vested Life (Years) Value Balance – January 1, 2020 4,907,223 4,907,223 $ 2.40 $ 2.40 $ 1.11 1.55 $ - Granted 14,485,595 - - - - - - Exercised (20,000 ) - - - - - - Cancelled - - - - - - - Balance – December 31, 2020 19,372,818 15,495,973 $ 1.62 $ 1.61 $ 0.81 4.07 $ - Granted 20,893,334 - - - - - - Exercised (1,451,025 ) - - - - - - Cancelled (3,181,052 ) - - - - - - Balance – December 31, 2021 35,634,075 35,629,908 $ 1.04 $ 1.04 $ 0.53 4.38 $ 71,737 Amendments to Notes and Warrants During the year ended December 31, 2020, the Company entered into amendments (the “Amendments”) with certain holders of the Company’s 8% Unsecured Promissory Notes (the “2018 Notes”) and Nontransferable Common Stock Purchase Warrants (the “2018 Warrants”). Pursuant to the Amendments, the maturity date of the applicable 2018 Notes was extended from March 29, 2021 to June 30, 2021 and the expiration date of the applicable 2018 Warrants was extended from March 29, 2021 to March 29, 2022. The terms of the applicable 2018 Notes were also amended to grant the holders of such 2018 Notes a right to participate in a future private offering of the Company’s securities upon terms substantially similar to those offered to investors in a future primary offering of the Company’s securities and to grant resale registration rights in connection therewith. The Company recognized $0.2 million of non-cash costs in Other Expenses in the accompanying statements of operations relating to the 2018 Warrants extension. The Company subsequently entered into a second amendment to the 2018 Notes with certain holders whereby the maturity date of the applicable 2018 Notes was extended from June 30, 2021 to June 30, 2022 and the expiration date of the applicable 2018 Warrants was extended from March 29, 2022 to March 29, 2026. The exercise price of the 2018 Warrants was adjusted from $5.30 per share to $2.00 per share. The terms of the applicable 2018 Notes were also amended to require that the holders of such 2018 Notes participate in a future private offering of the Company’s securities upon terms substantially similar to those offered to investors in a future primary offering of the Company’s securities (see Note 7 – Notes Payable). The Company also granted an additional warrant to purchase 0.5 of one share of its common stock, or 1.5 million shares of common stock in total, per dollar of each participating 2018 Note holder’s principal amount of the 2018 Notes with an exercise price of $2.00 per share and an expiration date of March 29, 2026 (the “New Warrants”). The New Warrants will be exercisable beginning on the six-month anniversary of the date of issuance, and the Company granted to the participating 2018 Note holders certain registration rights with respect to its securities issued in the Private Offering and the shares of common stock underlying the New Warrants. The Company recognized $0.5 million of non-cash costs in Other Expenses in the accompanying statements of operations related to this second amendment. Also, during the year ended December 31, 2020, the Company entered into amendments with certain holders of the Company’s Common Stock Purchase Warrants (the “2017 Warrants”) pursuant to which the expiration date of the applicable 2017 Warrants was extended from June 30, 2020 to September 30, 2021. The Company recognized $1.6 million of non-cash costs in Other Expenses in the accompanying statements of operations relating to the 2017 Warrants extension. The Company determined the proper classification of the loan modification based on ASC 470-50, Debt Modifications and Extinguishments. Because the change in present value of cash flows of the modified debt is less than 10% when compared to the present value of the cash flows of the original debt, no change is required to be made to the debt in the accompanying condensed financial statements. Employee Stock Purchase Plan The Company has an Employee Stock Purchase Plan (“ESPP”) in which employees may purchase shares with the amounts accumulated during the offering period from employee directed payroll deferrals. Purchases of the Company’s common stock are equal to 85% of the closing market price of its common stock on the first day or last day of the offering period, whichever is lower. During the year ended December 31, 2021, 17,662 shares were issued under the ESPP for $16,814 of employee compensation deferrals. As of December 31, 2021, 482,338 shares are available for future issuance under the ESPP.

Non-Cash Expenses

Non-Cash Expenses	12 Months Ended
	Dec. 31, 2021
Other Income and Expenses [Abstract]
NON-CASH EXPENSES	Note 11 – Non-Cash Expenses The following table details the Company’s non-cash expenses included in the accompanying statements of operations: For the 2021 2020 Operating expenses Stock-based compensation $ 2,543,712 $ 2,216,316 Depreciation & amortization 140,914 156,664 Subtotal $ 2,684,626 $ 2,372,980 Other expense Amortization of debt discount 31,687 504,498 Equity modification - 2,290,688 Subtotal $ 31,687 $ 2,795,186 Total non-cash expenses $ 2,716,313 $ 5,168,166

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2021
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	Note 12 – Subsequent Events Management has evaluated subsequent events to determine if events or transactions occurring through the date on which the financial statements were issued require adjustment or disclosure in the Company’s financial statements. Subsequent to December 31, 2021, the Company granted stock options to purchase a total of 0.4 million shares of the Company’s common stock with an exercise price of $0.43 per share. The stock options have a term of ten years with vesting over a four-year period. Subsequent to December 31, 2021, the Company sold 0.6 million shares of its common stock under its ATM program for proceeds of $0.2 million, net of commissions. Subsequent to December 31, 2021, the Company repaid a promissory note, held by a director of the Company, totaling approximately $0.5 million in principal and interest.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation All amounts are presented in U.S. Dollars.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at dates of the financial statements and the reported amounts of revenue and expenses during the periods. Actual results could differ from these estimates. The Company’s significant estimates and assumptions include the fair value of financial instruments, stock-based compensation and the valuation allowance relating to the Company’s deferred tax assets.
Concentrations of Credit Risk	Concentrations of Credit Risk The Company maintains deposits in a financial institution which is insured by the Federal Deposit Insurance Corporation (“FDIC”). At various times, the Company has deposits in this financial institution in excess of the amount insured by the FDIC. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk.
Investments	Investments Investments as of December 2021 and 2020 consist of U.S. Treasury Bills, which are classified as held-to-maturity, and Certificates of Deposit totaling $21.3 million and $18.1 million, respectively. The Company determines the appropriate balance sheet classification of its investments at the time of purchase and evaluates the classification at each balance sheet date. All of the Company’s U.S. Treasury Bills mature within the subsequent twelve months from the date of purchase. Unrealized gains and losses were de minimus
Capitalization of Patent Costs	Capitalization of Patent Costs The Company capitalizes the costs of its patents which consists of legal and filing fees related to the prosecution of patent filings. The patents will be amortized using the straight-line method over the estimated remaining lives of the patents which is 20 years from the initial filing of the patent.
Cash Equivalents	Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. As of December 31, 2021, the Company invested $0.7 million in Treasury Bills that are considered cash equivalents due to their maturity date being less than three months from the date of purchase.
Property and Equipment, net	Property and Equipment, net Property and equipment are stated at cost less accumulated depreciation. Depreciation of computer and lab equipment is computed by use of the straight-line method based on the estimated useful lives of the assets, which range from three to five years. Expenditures for maintenance and repairs that do not improve or extend the expected lives of the assets are expensed to operations, while expenditures for major upgrades to existing items are capitalized. Upon retirement or other disposition of these assets, the costs and accumulated depreciation are removed from the accounts and resulting gains or losses are reflected in the results of operations.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company measures the fair value of financial assets and liabilities based on the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company utilizes three levels of inputs that may be used to measure fair value: Level 1 - quoted prices in active markets for identical assets or liabilities. Level 2 - quoted prices for similar assets and liabilities in active markets or inputs that are observable. Level 3 - inputs that are unobservable (for example, cash flow modeling inputs based on assumptions). The carrying amounts of cash, investments and accounts payable approximate fair value due to the short-term nature of these instruments. The amount of debt included in the accompanying balance sheets approximates its fair value because the interest rate of the notes approximates the current market interest rate.
Common Stock Purchase Warrants	Common Stock Purchase Warrants The Company classifies as equity any contracts that (i) require physical settlement or net-share settlement or (ii) provides the Company with a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement) providing that such contracts are indexed to the Company’s own stock. The Company classifies as assets or liabilities any contracts that (i) require net-cash settlement (including a requirement to net cash settle the contract if an event occurs and if that event is outside the Company’s control), or (ii) gives the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement). The Company assesses classification of its common stock purchase warrants and other free-standing derivatives at each reporting date to determine whether a change in classification between assets, liabilities and equity is required. The Company’s free-standing derivatives consist of warrants to purchase common stock that were issued in connection with its notes payable and public and private offerings. The Company evaluated these warrants to assess their proper classification using the applicable criteria enumerated under U.S. GAAP and determined that the common stock purchase warrants meet the criteria for equity classification in the accompanying balance sheets as of December 31, 2021 and 2020.
Income Taxes	Income Taxes The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of items that have been included or excluded in the financial statements or tax returns. Deferred tax assets and liabilities are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (“temporary differences”) at enacted tax rates in effect for the years in which the temporary differences are expected to reverse. The benefit of tax positions taken or expected to be taken in income tax returns are recognized in the financial statements if such positions are more likely than not of being sustained. Management has evaluated and concluded that there were no material uncertain tax positions requiring recognition in the Company’s financial statements as of December 31, 2021 and 2020. The Company does not expect any significant changes in the unrecognized tax benefits within twelve months of the reporting date. The Company classifies interest expense and any related penalties related to income tax uncertainties as a component of income tax expense. No interest or penalties have been recognized during the years ended December 31, 2021 and 2020.
Research and Development Expenses	Research and Development Expenses The Company expenses all research and development expenses as incurred. These costs include payroll, employee benefits, supplies, contracted for lab services, depreciation and other personnel-related costs associated with product development.
Share-Based Payment	Share-Based Payment The Company accounts for share-based payments using the fair value method. For employees and directors, the fair value of the award is measured, as discussed below, on the grant date. For non-employees, fair value is generally valued based on the fair value of the services provided or the fair value of the equity instruments on the measurement date, whichever is more readily determinable. The Company has granted stock options at exercise prices equal to the closing price of the Company’s common stock as reported by Nasdaq, with input from management on the date of grant. Upon exercise of an option or warrant, the Company issues new shares of common stock out of its authorized shares. The weighted-average fair value of options and warrants has been estimated on the grant date or measurement date using the Black-Scholes pricing model. The fair value of each instrument is estimated on the grant date or measurement date utilizing certain assumptions for a risk-free interest rate, volatility and expected remaining lives of the awards. The risk-free interest rate used is the United States Treasury rate for the day of the grant having a term equal to the life of the equity instrument. Volatility was derived from the Company’s share price. The assumptions used in calculating the fair value of share-based payment awards represent management’s best estimates, but these estimates involve inherent uncertainties and the application of management judgment. As a result, if factors change and the Company uses different assumptions, the Company’s stock-based compensation expense could be materially different in the future. The Black-Scholes assumptions are as follows: For the 2021 2020 Expected life 6 years 6 years Risk free interest rate 0.90-1.38% 0.21-1.61% Expected volatility 91-92% 94-97% Expected dividend yield 0% 0% As of December 31, 2021, total unrecognized stock compensation expense was $6.0 million, which will be recognized as those options vest over a period of approximately four years. The amount of future stock option compensation expense could be affected by any future option grants or by any option holders leaving the Company before their grants are fully vested.
Net Loss Per Share of Common Stock	Net Loss Per Share of Common Stock Basic net loss per share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted net earnings per share reflects the potential dilution that could occur if securities or other instruments to issue common stock were exercised or converted into common stock. Potentially dilutive securities are excluded from the computation of diluted net loss per share as their inclusion would be anti-dilutive and consist of the following: As of 2021 2020 Options 10,992,335 7,469,891 Warrants 35,634,075 19,372,818 Totals 46,626,410 26,842,709
Recent Accounting Pronouncements	Recent Accounting Pronouncements In December 2019, the Financial Accounting Standards Board issued ASU No. 2019-12, “Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes” (“ASU 2019-12”), which is intended to simplify the accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. Upon adoption, ASU No. 2019-12 did not have an impact on the Company’s consolidated financial statements and related disclosures.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Schedule of black-scholes assumptions	For the 2021 2020 Expected life 6 years 6 years Risk free interest rate 0.90-1.38% 0.21-1.61% Expected volatility 91-92% 94-97% Expected dividend yield 0% 0%
Schedule of anti-dilutive securities excluded from computation of diluted net loss per share	As of 2021 2020 Options 10,992,335 7,469,891 Warrants 35,634,075 19,372,818 Totals 46,626,410 26,842,709

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
Schedule of Property and equipment	As of 2021 2020 Lab equipment $ 860,433 $ 860,433 Computer and equipment 72,062 65,665 Total property and equipment $ 932,495 $ 926,098 Less: accumulated depreciation (671,883 ) (532,094 ) Total property and equipment, net $ 260,612 $ 394,004

Intangible Assets (Tables)

Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of intangible assets	As of 2021 2020 Intangible assets: patents $ 23,963 $ 21,604 Less: amortization (4,654 ) (3,529 ) Total intangible assets, net $ 19,309 $ 18,075

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	12 Months Ended
	Dec. 31, 2021
Accrued Liabilities [Abstract]
Schedule of accrued liabilities	As of 2021 2020 Lab services & supplies $ 6,080 $ 917,194 Professional fees 73,090 44,171 Interest 112,932 162,731 Other 3,918 17,645 Total accrued liabilities $ 196,020 $ 1,141,741

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Schedule of deferred tax assets	As of 2021 2020 Current: Accrued expenses $ 144,077 $ 464,042 Stock compensation 1,800,762 869,815 Net operating loss carryforward 19,481,137 16,165,927 Research and development credit carry forward 252,536 548,983 Total deferred tax assets 21,678,512 18,048,767 Valuation allowance (21,678,512 ) (18,048,767 ) Deferred tax asset, net of valuation allowance $ - $ -
Schedule of statutory federal income tax rate	For the 2021 2020 U.S. statutory federal rate (21.0 )% (21.0 )% State income taxes, net of federal tax (7.0 )% (7.0 )% Federal tax rate change - % - % Permanent differences 2.5 % 0.4 % Prior year true-ups 2.7 % (0.4 )% R&D tax credit (0.1 )% (0.5 )% Change in valuation allowance 22.9 % 28.5 % Income tax provision (benefit) - % - %
Schedule of income tax provision	For the 2021 2020 Federal Current $ - $ - Deferred (2,723,112 ) (3,482,375 ) State and local Current - - Deferred (905,577 ) (1,158,072 ) Change in valuation allowance 3,628,689 4,640,447 Income tax provision (benefit) $ - $ -

Stockholders_ Equity (Tables)

Stockholders’ Equity (Tables)	12 Months Ended
	Dec. 31, 2021
Stockholders' Equity Note [Abstract]
Schedule of stock-based compensation	For the 2021 2020 Research and development $ 223,476 $ 604,107 General and administrative 2,320,236 1,612,209 Total $ 2,543,712 $ 2,216,316
Schedule of stock option activity	Weighted Average Aggregate Stock Options Exercise Price Fair Value Contractual Intrinsic Outstanding Exercisable Outstanding Exercisable Vested Life (Years) Value Balance – January 1, 2020 7,632,358 4,542,144 $ 2.21 $ 1.57 $ 1.57 6.44 $ - Granted 275,000 - - - - - - Exercised (223,924 ) - - - - - - Cancelled (213,543 ) - - - - - - Balance – December 31, 2020 7,469,891 5,390,431 $ 2.06 $ 1.68 $ 1.68 6.27 $ - Granted 6,314,000 - - - - - - Exercised (1,262,146 ) - - - - - - Cancelled (1,529,410 ) - - - - - - Balance – December 31, 2021 10,992,335 6,126,901 $ 1.71 $ 1.58 $ 1.58 6.27 $ 36,273
Schedule of stock options outstanding and exercisable	Grant Price Weighted Average Exercise Total Number Weighted Average From To Price Outstanding Exercisable Remaining Contractual Term $ 0.26 $ 2.02 $ 1.21 7,981,377 2,965,298 7.98 years $ 2.10 $ 4.60 $ 2.47 2,567,958 2,718,604 6.73 years $ 5.30 $ 8.86 $ 6.44 443,000 443,000 6.35 years Totals 10,992,335 6,126,901
Schedule of warrants activity	Weighted Average Aggregate Warrants Exercise Price Fair Value Contractual Intrinsic Outstanding Exercisable Outstanding Exercisable Vested Life (Years) Value Balance – January 1, 2020 4,907,223 4,907,223 $ 2.40 $ 2.40 $ 1.11 1.55 $ - Granted 14,485,595 - - - - - - Exercised (20,000 ) - - - - - - Cancelled - - - - - - - Balance – December 31, 2020 19,372,818 15,495,973 $ 1.62 $ 1.61 $ 0.81 4.07 $ - Granted 20,893,334 - - - - - - Exercised (1,451,025 ) - - - - - - Cancelled (3,181,052 ) - - - - - - Balance – December 31, 2021 35,634,075 35,629,908 $ 1.04 $ 1.04 $ 0.53 4.38 $ 71,737

Non-Cash Expenses (Tables)

Non-Cash Expenses (Tables)	12 Months Ended
	Dec. 31, 2021
Other Income and Expenses [Abstract]
Schedule of non-cash expenses	For the 2021 2020 Operating expenses Stock-based compensation $ 2,543,712 $ 2,216,316 Depreciation & amortization 140,914 156,664 Subtotal $ 2,684,626 $ 2,372,980 Other expense Amortization of debt discount 31,687 504,498 Equity modification - 2,290,688 Subtotal $ 31,687 $ 2,795,186 Total non-cash expenses $ 2,716,313 $ 5,168,166

Liquidity and Management_s Pl_2

Liquidity and Management’s Plans (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Liquidity And Managements Plan [Abstract]
Cash, cash equivalents and investments balance	$ 26,200,000
Working capital	25,300,000
Stockholders' equity	25,607,827	$ 18,487,155	$ 8,136,826
Incurred a net loss	$ (15,475,776)	$ (16,264,961)

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Summary of Significant Accounting Policies (Details) [Line Items]
U.S. treasury bills	$ 21.3	$ 18.1
Estimate life of Patent	20 years
Cash equivalents	$ 0.7
Unrecognized stock option compensation expense	$ 6
Minimum [Member] | Computer Equipment [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
Estimated useful life	3 years
Maximum [Member] | Lab Equipment [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
Estimated useful life	5 years

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details) - Schedule of black-scholes assumptions - Equity Option [Member]	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Summary of Significant Accounting Policies (Details) - Schedule of black-scholes assumptions [Line Items]
Expected life	6 years	6 years
Expected dividend yield	0.00%	0.00%
Minimum [Member]
Summary of Significant Accounting Policies (Details) - Schedule of black-scholes assumptions [Line Items]
Risk free interest rate	0.90%	0.21%
Expected volatility	91.00%	94.00%
Maximum [Member]
Summary of Significant Accounting Policies (Details) - Schedule of black-scholes assumptions [Line Items]
Risk free interest rate	1.38%	1.61%
Expected volatility	92.00%	97.00%

Summary of Significant Accoun_5

Summary of Significant Accounting Policies (Details) - Schedule of anti-dilutive securities excluded from computation of diluted net loss per share - shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of earnings per share, Amount	46,626,410	26,842,709
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of earnings per share, Amount	35,634,075	19,372,818
Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of earnings per share, Amount	10,992,335	7,469,891

Property and Equipment (Details

Property and Equipment (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 0.1	$ 0.2

Property and Equipment (Detai_2

Property and Equipment (Details) - Schedule of Property and equipment - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 932,495	$ 926,098
Less: accumulated depreciation	(671,883)	(532,094)
Total property and equipment, net	260,612	394,004
Lab equipment [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment	860,433	860,433
Computer and equipment [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 72,062	$ 65,665

Intangible Assets (Details)

Intangible Assets (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expense	$ 1,125	$ 1,079
Intangible amortization expense	1,226
Amortization expense total	$ 13,184

Intangible Assets (Details) - S

Intangible Assets (Details) - Schedule of intangible assets - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Schedule of intangible assets [Abstract]
Intangible assets: patents	$ 23,963	$ 21,604
Less: amortization	(4,654)	(3,529)
Total intangible assets, net	$ 19,309	$ 18,075

Accrued Liabilities (Details) -

Accrued Liabilities (Details) - Schedule of accrued liabilities - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Schedule of accrued liabilities [Abstract]
Lab services & supplies	$ 6,080	$ 917,194
Professional fees	73,090	44,171
Interest	112,932	162,731
Other	3,918	17,645
Total accrued liabilities	$ 196,020	$ 1,141,741

Notes Payable (Details)

Notes Payable (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Notes Payable (Details) [Line Items]
Interest rate	8.00%
Debt principal amount	$ 3.8
Issued unit (in Shares)	3.2
Debt instrument price (in Dollars per share)	$ 1.22
Aggregate principal amount	$ 0.4	$ 0.8
Aggregate principal amount due payable in June 2022	0.4
Repaid amount	$ 0.4
Warrant [Member]
Notes Payable (Details) [Line Items]
Exercise price (in Dollars per share)	$ 0.75
Common Stock [Member]
Notes Payable (Details) [Line Items]
Exercise price (in Dollars per share)	$ 1.44
Notes Payable [Member]
Notes Payable (Details) [Line Items]
Debt principal amount	$ 0.1
Issued unit (in Shares)	0.1

Commitments and Contingencies (

Commitments and Contingencies (Details) - USD ($)	1 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2021	Dec. 31, 2020
Commitments and Contingencies (Details) [Line Items]
Rent expense for space	$ 13,080
Rent expense		$ 0.4	$ 0.4
2011 Exclusive Agreement [Member]
Commitments and Contingencies (Details) [Line Items]
Milestone payment		$ 765,000
License reduced percentage		50.00%
Aggregate maintenance fees		$ 80,000
Maintenance fees annually		$ 50,000
Percentage of worldwide net sales		2.00%
Subject to a minimum royalty payment		$ 75,000
Royalty description		The Company is required to pay royalties ranging from 8% of worldwide sublicense sales of covered products (if the sublicense is entered after commencement of Phase II clinical trials) to 12% of worldwide sublicense sales (if the sublicense is entered prior to commencement of Phase I clinical trials).
2013 Exclusive Agreement [Member]
Commitments and Contingencies (Details) [Line Items]
Milestone payment		$ 765,000
License reduced percentage		50.00%
Aggregate maintenance fees		$ 7,500
Maintenance fees annually		$ 5,000
Percentage of worldwide net sales		2.00%
Subject to a minimum royalty payment		$ 75,000
Royalty description		The Company is required to pay the Regents royalties ranging from 8% of worldwide sublicense sales of covered products (if the sublicense is entered after commencement of Phase II clinical trials) to 12% of worldwide sublicense sales (if the sublicense is entered prior to commencement of Phase I clinical trials).
Initial license issue fee		$ 10,000

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Millions	1 Months Ended	12 Months Ended
	Mar. 27, 2020	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Change in valuation allowance		$ 3.6	$ 4.6
Net operating loss carryovers		$ 70	58
Operating loss carry forwards, description		The Company’s 2017 and prior federal and state net operating loss carry forwards, if not utilized, will begin to expire from 2029 to 2037. Beginning with 2018, and for subsequent years, the Company’s NOLs will have indefinite lives for federal tax purposes.
Research and development tax credits		$ 0.9	$ 0.9
Tax credits expire date description		These R&D tax credits will begin to expire from 2033 to 2040, respectively.
Tax cuts of taxable income, percentage	100.00%

Income Taxes (Details) - Schedu

Income Taxes (Details) - Schedule of deferred tax assets - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Current:
Accrued expenses	$ 144,077	$ 464,042
Stock compensation	1,800,762	869,815
Net operating loss carryforward	19,481,137	16,165,927
Research and development credit carry forward	252,536	548,983
Total deferred tax assets	21,678,512	18,048,767
Valuation allowance	(21,678,512)	(18,048,767)
Deferred tax asset, net of valuation allowance

Income Taxes (Details) - Sche_2

Income Taxes (Details) - Schedule of statutory federal income tax rate	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Schedule of statutory federal income tax rate [Abstract]
U.S. statutory federal rate	(21.00%)	(21.00%)
State income taxes, net of federal tax	(7.00%)	(7.00%)
Federal tax rate change
Permanent differences	2.50%	0.40%
Prior year true-ups	2.70%	(0.40%)
R&D tax credit	(0.10%)	(0.50%)
Change in valuation allowance	22.90%	28.50%
Income tax provision (benefit)

Income Taxes (Details) - Sche_3

Income Taxes (Details) - Schedule of income tax provision - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Federal
Current
Deferred	(2,723,112)	(3,482,375)
State and local
Current
Deferred	(905,577)	(1,158,072)
Change in valuation allowance	3,628,689	4,640,447
Income tax provision (benefit)

Stockholders_ Equity (Details)

Stockholders’ Equity (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Stockholders’ Equity (Details) [Line Items]
Authorized to issue and sale of stock	185,000,000
Common stock, shares authorized	180,000,000
Common stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Net realized under the ATM sales (in Dollars)	$ 2,900,000	$ 4,300,000
Incurred professional fees (in Dollars)	21,294	$ 200,000
Amount of ATM availability (in Dollars)	12,500,000
Aggregate grant date fair value (in Dollars)	$ 5,800,000
Description of pursuant agreement	Pursuant to such agreement, the Company granted Dr. Sarret (1) a time-based inducement nonqualified stock option to purchase 2.3 million shares of common stock and (2) a performance-based inducement nonqualified stock option to purchase 1.3 million shares of common stock (the “Inducement Awards”). The options have an exercise price of $1.35, and the time-based grant will vest as to 25% of the shares on the one-year anniversary of the grant date, May 3, 2021, with the remaining shares subject to the option vesting in 36 equal monthly installments. The time-based Inducement Award has an aggregate grant date fair value of $2.2 million. As of December 31, 2021, Dr. Sarret satisfied a portion of the performance conditions and vested performance-based stock options to purchase 0.7 million shares of the 1.3 million shares possible under the grant. The performance-based award had a fair value of $0.1 million.
Description of granted stock options		the Company granted stock options to employees to purchase 0.3 million shares of the Company’s common stock at exercise prices that ranged between $1.55 to $2.56 per share. The options have terms of ten years. The stock options have an aggregate grant date fair value of $0.5 million.
Warrants to purchase of common stock exercised	1,500,000
Warrants to purchase common stock expired and cancelled	3,200,000
Registration of shares, description		During the year ended December 31, 2020, the Company issued warrants to purchase 10.6 million shares of the Company’s common stock as part of the Public Offering (see Note 10 – Underwritten Public Offerings) and to the note holders that extended the due date of their unsecured promissory notes (see Note 10 – Amendments to Notes and Warrants) and warrants to purchase 2.4 million shares of the Company’s common stock as part of the Private Offering that converted outstanding amounts due under the Company’s 8% Unsecured Promissory Notes due 2021 (see Note 7 - Notes Payable).
Cash proceeds (in Dollars)	$ 26,200,000
Non-cash costs in other expenses (in Dollars)	$ 500,000	$ 1,600,000
Present value of cash flow of modified debt	10.00%
Closing market price percentage	85.00%
Issued shares of under ESPP	17,662
Employee compensation deferrals (in Dollars)	$ 16,814
Future issuance of shares under ESPP	482,338
Sales agreement [Member]
Stockholders’ Equity (Details) [Line Items]
Authorized to issue and sale of stock	1,700,000
Minimum [Member]
Stockholders’ Equity (Details) [Line Items]
Grant date prices (in Dollars per share)	$ 0.34
Maximum [Member]
Stockholders’ Equity (Details) [Line Items]
Grant date prices (in Dollars per share)	$ 1.38
2011 Plan [Member]
Stockholders’ Equity (Details) [Line Items]
Total number of shares authorized for issuance		14
Remaining options to be issued	3.2
Warrant [Member]
Stockholders’ Equity (Details) [Line Items]
Authorized to issue and sale of stock		2,400,000
Shares of common stock purchase	100,000
Cash proceeds (in Dollars)	$ 2,100,000
Exercise price (in Dollars per share)	$ 1.38
Vesting period, description	Fifty thousand of these warrants were valued using the Black-Scholes option pricing model and the corresponding expense will be recognized over the service period of three years. Ten thousand of these warrants were performance based. During the year ended December 31, 2021, the performance criteria were met and the warrants were valued and expensed at the time the performance conditions were met. The warrants have terms that range from two to three years with vesting over a one-year period.
Registration of shares, description	The Company subsequently entered into a second amendment to the 2018 Notes with certain holders whereby the maturity date of the applicable 2018 Notes was extended from June 30, 2021 to June 30, 2022 and the expiration date of the applicable 2018 Warrants was extended from March 29, 2022 to March 29, 2026. The exercise price of the 2018 Warrants was adjusted from $5.30 per share to $2.00 per share. The terms of the applicable 2018 Notes were also amended to require that the holders of such 2018 Notes participate in a future private offering of the Company’s securities upon terms substantially similar to those offered to investors in a future primary offering of the Company’s securities (see Note 7 – Notes Payable). The Company also granted an additional warrant to purchase 0.5 of one share of its common stock, or 1.5 million shares of common stock in total, per dollar of each participating 2018 Note holder’s principal amount of the 2018 Notes with an exercise price of $2.00 per share and an expiration date of March 29, 2026 (the “New Warrants”).
Purchase of warrants		20,000
Common Stock [Member]
Stockholders’ Equity (Details) [Line Items]
Cash proceeds (in Dollars)		$ 45,000
Underwritten Public Offerings [Member]
Stockholders’ Equity (Details) [Line Items]
Authorized to issue and sale of stock	20,800,000	10,600,000
Incurred professional fees (in Dollars)	$ 1,200,000	$ 1,400,000
Net of commissions (in Dollars)	$ 13,800,000	$ 13,700,000
Per share exercise price (in Dollars per share)	$ 0.72	$ 1.44
Underwritten Public Offerings [Member] | Warrant [Member]
Stockholders’ Equity (Details) [Line Items]
Authorized to issue and sale of stock	20,800,000	12,300,000
Stock Option [Member]
Stockholders’ Equity (Details) [Line Items]
Shares of common stock purchase	1,300,000	200,000
Cash proceeds (in Dollars)	$ 1,200,000	$ 300,000
Shares of common stock purchase	1,500,000	200,000
Stock Option [Member] | Common Stock [Member]
Stockholders’ Equity (Details) [Line Items]
Granted	6,300,000

Stockholders_ Equity (Details)

Stockholders’ Equity (Details) - Schedule of stock-based compensation - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Stockholders’ Equity (Details) - Schedule of stock-based compensation [Line Items]
Total	$ 2,543,712	$ 2,216,316
Research and development [Member]
Stockholders’ Equity (Details) - Schedule of stock-based compensation [Line Items]
Total	223,476	604,107
General and administrative [Member]
Stockholders’ Equity (Details) - Schedule of stock-based compensation [Line Items]
Total	$ 2,320,236	$ 1,612,209

Stockholders_ Equity (Details_2

Stockholders’ Equity (Details) - Schedule of stock option activity - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Schedule of stock option activity [Abstract]
Stock Options, Outstanding, Beginning Balance (in Shares)	7,469,891	7,632,358
Stock Options, Exercisable, Beginning Balance (in Shares)	5,390,431	4,542,144
Weighted Average, Exercise Price, Outstanding, Beginning Balance	$ 2.06	$ 2.21
Weighted Average, Exercise Price, Exercisable, Beginning Balance	1.68	1.57
Weighted Average, Fair Value Vested, Beginning Balance	$ 1.68	$ 1.57
Weighted Average, Contractual Life (Years), Beginning Balance		6 years 5 months 8 days
Aggregate Intrinsic Value, Beginning Balance (in Dollars)
Stock Options, Outstanding, Granted (in Shares)	6,314,000	275,000
Stock Options, Exercisable, Granted (in Shares)
Weighted Average, Exercise Price, Outstanding, Granted
Weighted Average, Exercise Price, Exercisable, Granted
Weighted Average, Fair Value Vested, Granted
Aggregate Intrinsic Value, Granted (in Dollars)
Stock Options, Outstanding, Exercised (in Shares)	(1,262,146)	(223,924)
Stock Options, Exercisable, Exercised (in Shares)
Weighted Average, Exercise Price, Outstanding, Exercised
Weighted Average, Exercise Price, Exercisable, Exercised
Weighted Average, Fair Value Vested, Exercised
Aggregate Intrinsic Value, Exercised (in Dollars)
Stock Options, Outstanding, Cancelled (in Shares)	(1,529,410)	(213,543)
Stock Options, Exercisable, Cancelled (in Shares)
Weighted Average, Exercise Price, Outstanding, Cancelled
Weighted Average, Exercise Price, Exercisable, Cancelled
Weighted Average, Fair Value Vested, Cancelled
Aggregate Intrinsic Value, Cancelled (in Dollars)
Stock Options, Outstanding, Ending Balance (in Shares)	10,992,335	7,469,891
Stock Options, Exercisable, Ending Balance (in Shares)	6,126,901	5,390,431
Weighted Average, Exercise Price, Outstanding, Ending Balance	$ 1.71	$ 2.06
Weighted Average, Exercise Price, Exercisable, Ending Balance	1.58	1.68
Weighted Average, Fair Value Vested, Ending Balance	$ 1.58	$ 1.68
Weighted Average, Contractual Life (Years), Ending Balance	6 years 3 months 7 days	6 years 3 months 7 days
Aggregate Intrinsic Value, Ending Balance (in Dollars)	$ 36,273

Stockholders_ Equity (Details_3

Stockholders’ Equity (Details) - Schedule of stock options outstanding and exercisable	12 Months Ended
	Dec. 31, 2021$ / sharesshares
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Stock Options, Weighted Average Exercise Price
Stock Options, Total Outstanding (in Shares) (in Shares) | shares	10,992,335
Stock Options, Number Exercisable (in Shares) (in Shares) | shares	6,126,901
Grant Price From 0.26 to 2.02 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Stock Options, Grant Price, Minimum	$ 0.26
Stock Options, Weighted Average Exercise Price	$ 1.21
Stock Options, Total Outstanding (in Shares) (in Shares) | shares	7,981,377
Stock Options, Number Exercisable (in Shares) (in Shares) | shares	2,965,298
Stock Options, Weighted Average Remaining Contractual Term	7 years 11 months 23 days
Stock Options, Grant Price, Maximum	$ 2.02
Grant Price From 2.10 to 4.60 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Stock Options, Grant Price, Minimum	2.1
Stock Options, Weighted Average Exercise Price	$ 2.47
Stock Options, Total Outstanding (in Shares) (in Shares) | shares	2,567,958
Stock Options, Number Exercisable (in Shares) (in Shares) | shares	2,718,604
Stock Options, Weighted Average Remaining Contractual Term	6 years 8 months 23 days
Stock Options, Grant Price, Maximum	$ 4.6
Grant Price From 5.30 to 8.86 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Stock Options, Grant Price, Minimum	5.3
Stock Options, Weighted Average Exercise Price	$ 6.44
Stock Options, Total Outstanding (in Shares) (in Shares) | shares	443,000
Stock Options, Number Exercisable (in Shares) (in Shares) | shares	443,000
Stock Options, Weighted Average Remaining Contractual Term	6 years 4 months 6 days
Stock Options, Grant Price, Maximum	$ 8.86

Stockholders_ Equity (Details_4

Stockholders’ Equity (Details) - Schedule of warrants activity - Warrant [Member] - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Class of Warrant or Right [Line Items]
Warrants, Outstanding, Beginning Balance (in Shares)	19,372,818	4,907,223
Warrants, Exercisable, Beginning Balance (in Shares)	15,495,973	4,907,223
Weighted Average, Exercise Price, Outstanding, Beginning Balance	$ 1.62	$ 2.4
Weighted Average, Exercise Price, Exercisable, Beginning Balance	1.61	2.4
Weighted Average, Fair Value Vested, Beginning Balance	$ 0.81	$ 1.11
Weighted Average, Contractual Life (Years), Beginning Balance		1 year 6 months 18 days
Aggregate Intrinsic Value, Beginning Balance (in Dollars)
Warrants, Outstanding, Ending Balance (in Shares)	35,634,075	19,372,818
Warrants, Exercisable, Ending Balance (in Shares)	35,629,908	15,495,973
Weighted Average, Exercise Price, Outstanding, Ending Balance	$ 1.04	$ 1.62
Weighted Average, Exercise Price, Exercisable, Ending Balance	1.04	1.61
Weighted Average, Fair Value Vested, Ending Balance	$ 0.53	$ 0.81
Weighted Average, Contractual Life (Years), Ending Balance	4 years 4 months 17 days	4 years 25 days
Aggregate Intrinsic Value, Ending Balance (in Dollars)	$ 71,737
Warrants, Outstanding, Granted (in Shares)	20,893,334	14,485,595
Warrants, Exercisable, Granted (in Shares)
Weighted Average, Exercise Price, Outstanding, Granted
Weighted Average, Exercise Price, Exercisable, Granted
Weighted Average, Fair Value Vested, Granted
Aggregate Intrinsic Value, Granted (in Dollars)
Warrants, Outstanding, Exercised (in Shares)	(1,451,025)	(20,000)
Warrants, Exercisable, Exercised (in Shares)
Weighted Average, Exercise Price, Outstanding, Exercised
Weighted Average, Exercise Price, Exercisable, Exercised
Weighted Average, Fair Value Vested, Exercised
Aggregate Intrinsic Value, Exercised (in Dollars)
Warrants, Outstanding, Cancelled (in Shares)	(3,181,052)
Warrants, Exercisable, Cancelled (in Shares)
Weighted Average, Exercise Price, Outstanding, Cancelled
Weighted Average, Exercise Price, Exercisable, Cancelled
Weighted Average, Fair Value Vested, Cancelled
Aggregate Intrinsic Value, Cancelled (in Dollars)

Non-Cash Expenses (Details) - S

Non-Cash Expenses (Details) - Schedule of non-cash expenses - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Operating expenses:
Stock-based compensation	$ 2,543,712	$ 2,216,316
Depreciation & amortization	140,914	156,664
Subtotal	2,684,626	2,372,980
Other expense:
Amortization of debt discount	31,687	504,498
Equity modification		2,290,688
Subtotal	31,687	2,795,186
Total non-cash expenses	$ 2,716,313	$ 5,168,166

Subsequent Events (Details)

Subsequent Events (Details) shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2021USD ($)shares
Subsequent Events (Details) [Line Items]
Net commissions	$ 0.2
Principle and interest	$ 0.5
Warrant [Member]
Subsequent Events (Details) [Line Items]
Warrants, description	the Company granted stock options to purchase a total of 0.4 million shares of the Company’s common stock with an exercise price of $0.43 per share. The stock options have a term of ten years with vesting over a four-year period.
ATM program [Member]
Subsequent Events (Details) [Line Items]
Purchase shares (in Shares) | shares	0.6